The Path to Perfect Pediatric Posology - Drug Development in Pediatrics.

Area of Science:

• Pediatric pharmacology
• Clinical trial design
• Regulatory science

Background:

• Limited enrollment of pediatric subjects in clinical trials creates significant gaps in medication dosing, safety, and efficacy data.
• Pediatric drug information is often restricted to narrow age ranges and may be insufficient due to age-related physiological differences.

Purpose of the Study:

• To address the challenges in pediatric drug development and information gathering.
• To highlight regulatory requirements for pediatric plans in drug development.
• To discuss the complexities and methodologies for extrapolating adult data to pediatric populations.

Main Methods:

• Review of current regulations requiring early pediatric plan submission (EU Phase 1, US Phase 2).
• Analysis of factors influencing the extrapolation of adult efficacy data to pediatric age groups.
• Examination of the necessity for direct pharmacokinetic and safety data collection in children.
• Identification of novel methodologies such as physiologically based pharmacokinetic modeling and population pharmacokinetics.

Main Results:

• Extrapolation of efficacy is possible for conditions with similar pathology across age groups but not for conditions absent in adults.
• Pharmacokinetic and safety data cannot be extrapolated and require dedicated collection in pediatric populations.
• New methodologies are being employed to overcome data gaps in pediatric therapeutics.

Conclusions:

• Early and comprehensive planning is essential for pediatric drug development.
• Direct data collection is critical for pediatric pharmacokinetics and safety.
• Innovative methods are vital for advancing pediatric pharmacotherapeutics and ensuring safe medication use in children.